LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Operating Cash Flow
Cash generated by the company's core business operations during the period.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $33.58M (cash outflow) rose 109.2% year over year, ahead of the +68.3% change in trailing-twelve-month operating cash flow. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at -7.7% a year.
Context
- Operating cash flow amounted to 362.4% of revenue in FY2025.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +109.2% holds above the trailing-twelve-month pace of +68.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (69.17M) USD
- Year-over-year change
- -16.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (69.17M) | -16.5% |
| FY2024 | 2024-12-31 | (59.39M) | +1.6% |
| FY2023 | 2023-12-31 | (60.38M) | +31.4% |
| FY2022 | 2022-12-31 | (87.98M) | -66.5% |
| FY2021 | 2021-12-31 | (52.85M) | — |
Operating Cash Flow vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +68.3% is the 3rd highest of 11, against a peer median of +15.8%.
- Operating cash flow amounts to 413.1% of revenue for LENZ, versus a peer median of 88.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $175.07M USD | +754.7% | +62.1% | 176.9% |
| LTM Mar 2026 | $156.42M USD | +50.4% | +7.2% | 3877.5% | |
| LTM Mar 2026 | $125.96M USD | -38.4% | -4.5% | 64.2% | |
| LTM Mar 2026 | $106.89M USD | +11.8% | +43.0% | — | |
| LTM Mar 2026 | $102.26M USD | +39.7% | +23.7% | — | |
| LTM Mar 2026 | $86.7M USD | +68.3% | -7.7% | 413.1% | |
| LTM Mar 2026 | $73.48M USD | +12.0% | +20.4% | — | |
| LTM Mar 2026 | $46.33M USD | +12.3% | +18.5% | — | |
| LTM Mar 2026 | $34.36M USD | -41.7% | +3.9% | 17.9% | |
| FY2025 | €33.42M EUR | +70.9% | -3.4% | 112.7% | |
| LTM Jun 2026 | $25.26M USD | +19.4% | — | 12.1% | |
| Peer median (excluding LENZ) | — | +15.8% | +18.5% | 88.5% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.76M) | (101.05M) | (69.97M) | (49.77M) | (82.13M) |
| Depreciation & Amortization | 734K | 8.35M | 15K | 58K | (3.12M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 1.34M | 6.37M | 12.55M |
| Change in Working Capital | (2.5M) | (7.21M) | 9.41M | (13.09M) | 3.25M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (329K) |
| Inventory | 0 | 0 | 0 | 0 | (4.28M) |
| Accounts Payables | 1.83M | 194K | 856K | (4.28M) | (90K) |
| Other Working Capital | (4.32M) | (7.4M) | 8.55M | (8.81M) | 7.95M |
| Other Non-Cash Items | 19.67M | 11.93M | (1.18M) | (2.95M) | 279K |
| Operating Cash Flow | (52.85M) | (87.98M) | (60.38M) | (59.39M) | (69.17M) |
| Capital Expenditures | (5.74M) | (6.59M) | (30K) | (468K) | (827K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (405.52M) | (52.09M) | (241.91M) | (280.8M) |
| Sales of Investments | 0 | 170.25M | 22.5M | 87.9M | 205.96M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.74M) | (241.86M) | (29.62M) | (154.48M) | (75.67M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 417.16M | 676K | 203K | 79.51M | 149.75M |
| Common Stock Repurchased | 0 | (79K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 306K | 0 | (2.48M) | 119.49M | 0 |
| Financing Cash Flow | 417.47M | 597K | 80.7M | 199M | 149.75M |
| Effect of Forex Changes | (1.72M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 357.16M | (329.25M) | (9.3M) | (14.87M) | 4.91M |
| Free Cash Flow | (58.59M) | (94.57M) | (60.41M) | (59.86M) | (70M) |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.